A 2.5% hip-and-knee market, a late diagnosis, and a CEO handoff — the growth algorithm resets
SYK · Earnings Call · 2026-10-29
The confession, not the crash
For four years Stryker grew organically near double digits and trained investors to treat orthopedics as a share-gaining machine. The third quarter broke that habit. Organic growth was 7.7%, with MedSurg and Neurotechnology at 9.1% and Orthopaedics at 5.9%; US knees grew 1.3% and US hips declined 0.6%. Management cut full-year organic growth to 6.5%-7% and adjusted EPS to $14.80-$14.90. The stock had already absorbed much of the bad news: it sits 22.7% below its July 2025 peak and is roughly flat over the last 90 days, 11.5% below its July 2026 high. At 22.2x operating income, the multiple is down nearly half year over year. This was not a crash; it was a confession.
Market or mirror?
The central question is whether Stryker ran into a softer end market or its own reflection. Kevin Lobo's answer to Robbie Marcus is unusually candid:
It is hard to estimate exactly, but I would say market growth is kind of in the 2.5% range this year. That is what we think, which is definitely a step down from where it has been the last five or six years.
That is a real call on affordability: higher insurance premiums and deductibles, more pre-authorization denials, softness in Europe and the Middle East. The phrase market slowdown now tops the company's narrative, alongside joint replacement and the knee market. But the same answer carries an admission that “it took us a while to figure this out” — Kevin Lobo, Chairman and Chief Executive Officer · 2026-10-29, because the cyber event and the SAP implementation in orthopedics delayed order entries and obscured visibility until early September. That is not just macro. It is a control failure in the company's most important commercial engine.
The contrast with prior calls is stark. In July, Lobo told investors: “We see the procedure environment as healthy in the businesses where we operate.” — Kevin A. Lobo, Chairman & CEO · 2026-07-30 In April, he said “We did not see a pause in orders.” — Kevin Lobo, Chairman & Chief Executive Officer · 2026-04-30 In January, Jason Beach said “volumes continue to be robust.” — Jason Beach, Vice President of Finance and Investor Relations · 2026-01-29 For several quarters the message was stable demand, elevated backlog, no cancellations. Now the message is a 2.5% hip-and-knee market and “we have not been winning at our historical rate” — Kevin Lobo, Chairman and Chief Executive Officer · 2026-10-29. The market may genuinely have slowed; Stryker's mirror was also fogged. That matters for 2027, because the promise of growing at the high end of its markets rests on a read of demand management just admitted it saw late.
The bulk-sales tell
One new phrase deserves more attention than it got. Asked about price competition, Lobo pushed back: “We don't do bulk sales.” — Kevin Lobo, Chairman and Chief Executive Officer · 2026-10-29 He argued Stryker reports actual price and actual demand, while some competitors use bulk sales that can exaggerate underlying trends. The keyword bulk sales is new in the company's top-thirty vocabulary, and it is a tell. If Stryker's numbers are cleaner, then weak hips and knees are a more honest read on the end market than a peer's flattered growth — and Stryker has less cushion to manage a slowdown through channel timing. Management still expects stable pricing: modest positive price in MedSurg, slightly negative in orthopedics. Clean reporting is a virtue; it does not create growth.
Mako and the execution tax
The robot franchise is not broken. US OrthoTech grew 18%, Mako sales were strong, and Mako Shoulder is getting good feedback on Mako 4. But the new products meant to extend the moat are lagging. Lobo conceded that “Mako RPS, is off to a slow start” — Kevin Lobo, Chairman and Chief Executive Officer · 2026-10-29 despite strong customer feedback, because the sales force was distracted. Triathlon Gold is also behind expectations. Mako RPS now reads as a launch needing a commercial reset, not a demand problem. That is the execution tax of the cyber and SAP disruptions: capital demand remains strong and the order book elevated, with management saying it is not draining backlog, but the selling organization lost a step at the worst moment.
Offsets and the handoff
The offsets are real but early. The vascular business improved sequentially, helped by one-time China joint-venture revenue and supply restoration; AVS's IVL platform is expected to begin commercializing in 2027, with PEERLESS II data also due. The investment in CMR Surgical gives Stryker an exclusive US sales role for the Versius soft-tissue robot and an option to buy later. Lobo was explicit that “our hope and our plan is that we will eventually purchase this” — Kevin Lobo, Chairman and Chief Executive Officer · 2026-10-29, but the structure is deliberately de-risked. ZuriMED adds a tuck-in for rotator-cuff repair. Capital allocation remains shareholder-friendly: $1 billion of buybacks in Q3 and a new $3 billion authorization, with M&A still the first priority.
The margin engine is the ballast. Q3 gross margin was 65.4%, up 40 basis points, and operating margin was 26.2%, up 60 basis points, even as sales missed. The last filed quarter still showed revenue of $6.6 billion, up 9% and operating income of $1.7 billion, up 49%. This is why the stock has not collapsed further. But the handoff to Spencer Stiles, with Lobo closing out 57 quarters, means the next CEO inherits a slower base and a credibility test on commercial execution.
What to watch
Stryker is not expensive against its own history: 4.7x revenue and 25.2% operating margin in the last filed quarter. But cheap versus history is not the same as cheap versus a slower growth algorithm. The bull case needs proof that SAP is behind the company, that share gains return in hips and knees, that Mako RPS and Triathlon Gold reaccelerate, and that AVS and CMR become real 2027 catalysts. Until then, the risk is that market growth becomes the new cyber event — a phrase that explains a miss but lingers for quarters. Stryker's clean numbers are a virtue; they also leave nowhere to hide.